Colin Love

Colin Love is the current Chief Operating Officer at Replimune. Prior to joining Replimune, Colin served as the Vice President of R&D Operations at Amgen from January 2011 to July 2015. In this role, Colin was responsible for developing Replimune's second generation oncolytic vaccines. Prior to their time at Amgen, Colin served as the Senior Vice President of Development at BioVex from September 2000 to April 2011. In this role, Colin provided product development consultancy support to a range of clients from small gene therapy start-ups to large established biotech companies. Prior to their time at BioVex, Colin served as the Director of Manufacturing Development at Celltech from January 1999 to September 2000. In this role, Colin was responsible for the development of Medeva Pharma's project management program. Prior to their time at Celltech, Colin served as the Director of Analytical Development at Medeva from January 1993 to December 1997. In this role, Colin was responsible for the development and implementation of Serono's R&D management program. Prior to their time at Serono, Colin served as a Project Manager at Amersham International from January 1982 to December 1987. In this role, Colin was responsible for the development and implementation of Amersham's analytical development program.

Colin Love received their Doctor of Philosophy (Ph.D.) in Biochemistry from the University of Glasgow.

Colin Love reports to Philip Astley-Sparke, CEO & Chairman. Colin Love works with Sushil Patel - CCO, Andrea Pirzkall - Chief Medical Officer, and Robert Coffin - Founder, President and Chief Research & Development Officer.